Efficacy and tolerance of 400 mg Bezafibrate in diabetic and hyperlipidaemic patients

J. Lakatos, M. Molnár, K. Tóth

Research output: Contribution to journalArticle

Abstract

The authors report the results of an open clinical study using 400 mg Bezafibrate once a day. Among 25 diabetic patients (type II.) underwent a 4 weeks period with nutritional advice. Average changes from inclusion levels were -24% for total cholesterol, -56% for triglicerides, +11.9% for HDL-cholesterol, -19% for plama fibrinogen In conclusion, bezafibrate at a daily dose of 400 mg had significant lipid-modifying properties but also exhibited a beneficial effect on other related risk factors such as fibrinogen reduction.

Original languageEnglish
Pages (from-to)433-435
Number of pages3
JournalActa Physiologica Hungarica
Volume84
Issue number4
Publication statusPublished - 1996

Fingerprint

Bezafibrate
Fibrinogen
HDL Cholesterol
Cholesterol
Lipids
Clinical Studies

Keywords

  • Bezafibrate
  • Fibrinogen
  • Lipoproteins
  • Risk factors

ASJC Scopus subject areas

  • Physiology

Cite this

Efficacy and tolerance of 400 mg Bezafibrate in diabetic and hyperlipidaemic patients. / Lakatos, J.; Molnár, M.; Tóth, K.

In: Acta Physiologica Hungarica, Vol. 84, No. 4, 1996, p. 433-435.

Research output: Contribution to journalArticle

@article{41c2922beb904b08a2b2b3a4d6af3d50,
title = "Efficacy and tolerance of 400 mg Bezafibrate in diabetic and hyperlipidaemic patients",
abstract = "The authors report the results of an open clinical study using 400 mg Bezafibrate once a day. Among 25 diabetic patients (type II.) underwent a 4 weeks period with nutritional advice. Average changes from inclusion levels were -24{\%} for total cholesterol, -56{\%} for triglicerides, +11.9{\%} for HDL-cholesterol, -19{\%} for plama fibrinogen In conclusion, bezafibrate at a daily dose of 400 mg had significant lipid-modifying properties but also exhibited a beneficial effect on other related risk factors such as fibrinogen reduction.",
keywords = "Bezafibrate, Fibrinogen, Lipoproteins, Risk factors",
author = "J. Lakatos and M. Moln{\'a}r and K. T{\'o}th",
year = "1996",
language = "English",
volume = "84",
pages = "433--435",
journal = "Physiology International",
issn = "2498-602X",
publisher = "Akademiai Kiado",
number = "4",

}

TY - JOUR

T1 - Efficacy and tolerance of 400 mg Bezafibrate in diabetic and hyperlipidaemic patients

AU - Lakatos, J.

AU - Molnár, M.

AU - Tóth, K.

PY - 1996

Y1 - 1996

N2 - The authors report the results of an open clinical study using 400 mg Bezafibrate once a day. Among 25 diabetic patients (type II.) underwent a 4 weeks period with nutritional advice. Average changes from inclusion levels were -24% for total cholesterol, -56% for triglicerides, +11.9% for HDL-cholesterol, -19% for plama fibrinogen In conclusion, bezafibrate at a daily dose of 400 mg had significant lipid-modifying properties but also exhibited a beneficial effect on other related risk factors such as fibrinogen reduction.

AB - The authors report the results of an open clinical study using 400 mg Bezafibrate once a day. Among 25 diabetic patients (type II.) underwent a 4 weeks period with nutritional advice. Average changes from inclusion levels were -24% for total cholesterol, -56% for triglicerides, +11.9% for HDL-cholesterol, -19% for plama fibrinogen In conclusion, bezafibrate at a daily dose of 400 mg had significant lipid-modifying properties but also exhibited a beneficial effect on other related risk factors such as fibrinogen reduction.

KW - Bezafibrate

KW - Fibrinogen

KW - Lipoproteins

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=0030310044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030310044&partnerID=8YFLogxK

M3 - Article

C2 - 9328624

AN - SCOPUS:0030310044

VL - 84

SP - 433

EP - 435

JO - Physiology International

JF - Physiology International

SN - 2498-602X

IS - 4

ER -